BR0312712A - Aminoácido modificado para a inibição da agregação plaquetária - Google Patents

Aminoácido modificado para a inibição da agregação plaquetária

Info

Publication number
BR0312712A
BR0312712A BR0312712-5A BR0312712A BR0312712A BR 0312712 A BR0312712 A BR 0312712A BR 0312712 A BR0312712 A BR 0312712A BR 0312712 A BR0312712 A BR 0312712A
Authority
BR
Brazil
Prior art keywords
platelet aggregation
amino acid
modified amino
inhibition
inhibiting
Prior art date
Application number
BR0312712-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Simon David Bateman
Moise Azria
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0312712A publication Critical patent/BR0312712A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0312712-5A 2002-07-17 2003-07-16 Aminoácido modificado para a inibição da agregação plaquetária BR0312712A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39689802P 2002-07-17 2002-07-17
PCT/EP2003/007739 WO2004006907A1 (en) 2002-07-17 2003-07-16 Modified amino acid for the inhibition of platelet aggregation

Publications (1)

Publication Number Publication Date
BR0312712A true BR0312712A (pt) 2005-04-26

Family

ID=30116066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312712-5A BR0312712A (pt) 2002-07-17 2003-07-16 Aminoácido modificado para a inibição da agregação plaquetária

Country Status (12)

Country Link
US (3) US20060106110A1 (enExample)
EP (1) EP1556027B1 (enExample)
JP (1) JP4541884B2 (enExample)
CN (1) CN1668290B (enExample)
AT (1) ATE538782T1 (enExample)
AU (1) AU2003257473A1 (enExample)
BR (1) BR0312712A (enExample)
CA (1) CA2492378C (enExample)
ES (1) ES2379949T3 (enExample)
PT (1) PT1556027E (enExample)
TW (1) TW200403052A (enExample)
WO (1) WO2004006907A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
DK1907571T3 (en) 2005-06-15 2017-08-21 Complete Genomics Inc NUCLEIC ACID ANALYSIS USING INCIDENTAL MIXTURES OF NON-OVERLAPPING FRAGMENTS
PE20070548A1 (es) * 2005-09-19 2007-07-12 Emisphere Tech Inc Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
EP2057112B1 (en) 2006-08-31 2018-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP2059260B1 (en) * 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
US8022048B2 (en) 2007-11-02 2011-09-20 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
EP2538945A4 (en) * 2010-02-24 2013-07-24 Emisphere Tech Inc Oral b12 therapy
RU2504536C1 (ru) * 2012-08-20 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Производное амида салициловой кислоты, обладающее антибактериальной, противогрибковой и антилизоцимной активностью

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260321A (en) * 1984-11-12 1993-11-09 Sandoz Ltd. Use of 1,4-dihydropyridine derivatives and combinations thereof with calcitonins
US5733647A (en) * 1992-11-05 1998-03-31 Polymer Innovations, Inc. Insole
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
ATE383169T1 (de) * 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents

Also Published As

Publication number Publication date
CA2492378A1 (en) 2004-01-22
CA2492378C (en) 2011-06-14
WO2004006907A1 (en) 2004-01-22
CN1668290B (zh) 2010-04-28
TW200403052A (en) 2004-03-01
JP4541884B2 (ja) 2010-09-08
JP2005535670A (ja) 2005-11-24
PT1556027E (pt) 2012-04-10
ATE538782T1 (de) 2012-01-15
US20060106110A1 (en) 2006-05-18
US20120088833A1 (en) 2012-04-12
EP1556027A1 (en) 2005-07-27
EP1556027B1 (en) 2011-12-28
AU2003257473A1 (en) 2004-02-02
CN1668290A (zh) 2005-09-14
ES2379949T3 (es) 2012-05-07
US20080280817A1 (en) 2008-11-13
US8664211B2 (en) 2014-03-04

Similar Documents

Publication Publication Date Title
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
DK1565471T3 (da) Quionolinylpyrazoler
UY27300A1 (es) Nuevos derivados de quinolina
CY1109523T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα παραγωγο βενζοδιαζεπινης και εναν αναστολεα της πρωτεϊνης συντηξης rsv
WO2007126964A3 (en) Kinase inhibitors
BR0308188A (pt) Forma de administração a ser aplicada oralmente, para substâncias ativas básicas de difìcil solubilidade
DE602005016532D1 (de) Pharmazeutische zusammensetzung mit einem benzodiaeins
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
UY27462A1 (es) Derivados de quinolina
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
EA200301276A1 (ru) Новые производные сульфоновых кислот
EP1602645A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVE WITH 2,6-DISUBSTITUTED STYRYL REST
AU2003257473A1 (en) Modified amino acid for the inhibition of platelet aggregation
BRPI0507735A (pt) composição para administração oral de cloridrato de tamsulosin e formulação de gránulo de liberação controlada compreendendo a mesma
PT966285E (pt) Utilizacao de (+)mefloquina para o tratamento da malaria
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
ES2190985T3 (es) Tratamiento de migraña por administracion de acido alfa-lipoico o de derivados del mismo.
UY28457A1 (es) Nueva composición
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/07/2017, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2523 DE 14-05-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.